NYSE:KVUE - Get Free Report ) announced its quarterly earnings data on Tuesday. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03, Briefing.com reports. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $3.79 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business's quarterly revenue was down 24.9% compared to the same quarter last year. Kenvue updated its FY24 guidance to $1.10-$1.20 EPS.
Get Kenvue alerts:
Sign Up
Kenvue Price Performance Kenvue stock traded up $0.37 during mid-day trading on Wednesday, reaching $20.45. 23,642,579 shares of the company's stock were exchanged, compared to its average volume of 17,121,814. The business's fifty day simple moving average is $19.85 and its 200 day simple moving average is $20.11. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. Kenvue has a one year low of $17.82 and a one year high of $27.80.
Kenvue Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 3.91%. The ex-dividend date is Tuesday, May 7th.
Analyst Upgrades and Downgrades A number of research firms recently weighed in on KVUE. JPMorgan Chase & Co. dropped their price target on Kenvue from $25.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 9th. William Blair started coverage on Kenvue in a report on Wednesday, April 3rd. They issued a "market perform" rating on the stock. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They issued an "underperform" rating and a $18.00 price target for the company. Royal Bank of Canada lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an "outperform" rating on the stock in a report on Friday, February 9th. Finally, HSBC lifted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a "hold" rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $24.38.
Check Out Our Latest Research Report on KVUE
Kenvue Company Profile (
Get Free Report )
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
